Cantor Fitzgerald Trims Marinus Pharmaceuticals (NASDAQ:MRNS) Target Price to $4.00

Marinus Pharmaceuticals (NASDAQ:MRNS) had its price target cut by Cantor Fitzgerald from $13.00 to $4.00 in a report released on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. StockNews.com upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, October 4th. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday, September 23rd. Finally, EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $6.36.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock traded up $0.01 during mid-day trading on Friday, hitting $0.30. The stock had a trading volume of 10,877,603 shares, compared to its average volume of 1,352,097. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26. The company’s 50-day simple moving average is $1.57 and its 200-day simple moving average is $1.67. The firm has a market cap of $16.65 million, a PE ratio of -0.11 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The company had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same quarter last year, the business earned ($0.61) EPS. On average, analysts expect that Marinus Pharmaceuticals will post -1.93 EPS for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the second quarter valued at approximately $28,000. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $34,000. AQR Capital Management LLC lifted its position in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Marinus Pharmaceuticals during the second quarter valued at approximately $64,000. Finally, Values First Advisors Inc. lifted its position in Marinus Pharmaceuticals by 501.8% during the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 52,257 shares in the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.